Physician profile
Matthew S Luff
NPI 1538246822
$859.61
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $145 · 2021: $204 · 2022: $382.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $444.50 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.40 | 2019-2022 | |
| Medtronic, INC. | $47.79 | 2021-2022 | |
| Abiomed | $39.77 | 2019-2020 | |
| Cardiovascular Systems INC. | $29.42 | 2020 | |
| Janssen Pharmaceuticals, INC | $29.29 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.14 | 2019 | |
| Abbott Laboratories | $17.78 | 2020 | |
| Esperion Therapeutics, INC. | $14.35 | 2020 | |
| Gilead Sciences, INC. | $11.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Luff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.